Jul 9, 2024 8:01am EDT Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
May 15, 2024 8:01am EDT Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors